Rigel Pharmaceuticals (RIGL) EBT Margin (2010 - 2026)
Rigel Pharmaceuticals' quarterly EBT Margin came in at 19.82% in Q1 2026, down 176.0% year-on-year from 26.08% in Q1 2025, and down 39.1% quarter-over-quarter from 32.54% in Q4 2025.
Rigel Pharmaceuticals has reported EBT Margin for 16 years, with the latest figure at 19.82% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 176.0% year-over-year to 19.82%; the trailing twelve-month figure through Mar 2026 stood at 40.69% (up 2192.0% YoY), and the FY2025 full-year result was 41.4%, up 3115.0% from the prior year.
- EBT Margin for Q1 2026 stood at 19.82%, down from 32.54% in the prior quarter.
- The five-year high for EBT Margin was 58.99% in Q2 2025, with the low at 164.0% in Q1 2022.
- Average EBT Margin over 5 years is 11.48%, with a median of 2.06% recorded in 2023.
- Peak annual rise in EBT Margin reached 11396 bps in 2022, while the deepest fall reached 21494 bps in 2022.
- Tracing RIGL's EBT Margin over 5 years: stood at 2.73% in 2022, then fell by 25 bps to 2.06% in 2023, then surged by 1184 bps to 26.43% in 2024, then gained by 23 bps to 32.54% in 2025, then tumbled by 39 bps to 19.82% in 2026.
- The last three EBT Margin figures came in at 19.82% (Q1 2026), 32.54% (Q4 2025), and 39.76% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 19.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.82% |
| Dec 31, 2025 | 32.54% |
| Sep 30, 2025 | 39.76% |
| Jun 30, 2025 | 58.99% |
| Mar 31, 2025 | 21.58% |
| Dec 31, 2024 | 26.43% |
| Sep 30, 2024 | 22.46% |
| Jun 30, 2024 | -2.80% |
| Mar 31, 2024 | -27.92% |
| Dec 31, 2023 | 2.06% |
| Sep 30, 2023 | -20.23% |
| Jun 30, 2023 | -24.55% |
| Mar 31, 2023 | -51.92% |
| Dec 31, 2022 | 2.73% |
| Sep 30, 2022 | -84.95% |
| Jun 30, 2022 | -45.25% |
| Mar 31, 2022 | -164.00% |
| Dec 31, 2021 | -111.23% |
| Sep 30, 2021 | -97.89% |
| Jun 30, 2021 | -56.31% |
| Mar 31, 2021 | 50.94% |
| Dec 31, 2020 | -104.27% |
| Sep 30, 2020 | -77.08% |
| Jun 30, 2020 | -109.71% |
| Mar 31, 2020 | 38.10% |
| Dec 31, 2019 | -111.69% |
| Sep 30, 2019 | -55.09% |
| Jun 30, 2019 | -198.00% |
| Mar 31, 2019 | -139.40% |
| Dec 31, 2018 | 8.53% |
| Sep 30, 2018 | -488.51% |
| Jun 30, 2018 | -1,430.16% |
| Dec 31, 2017 | 576.96% |
| Sep 30, 2017 | -1,962.22% |
| Mar 31, 2017 | -447.71% |
| Dec 31, 2016 | -522.60% |
| Sep 30, 2016 | -601.84% |
| Jun 30, 2016 | -157.47% |
| Mar 31, 2016 | -347.27% |
| Dec 31, 2015 | -148.61% |
| Sep 30, 2015 | -51.76% |
| Jun 30, 2015 | -268.36% |
| Mar 31, 2015 | -835.31% |
| Dec 31, 2013 | -293.51% |
| Jun 30, 2013 | -1,626.29% |
| Jun 30, 2012 | -1,649.20% |
| Mar 31, 2012 | -3,089.87% |
| Sep 30, 2011 | -411.73% |
| Jun 30, 2011 | -5,436.46% |
| Sep 30, 2010 | 69.77% |
| Jun 30, 2010 | 54.65% |